Grünenthal Group

  • Aussender Logo
  • Grünenthal Group
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

Aachen, Germany & Yeoju, South Korea (OTE) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its...

  • 05.03.2026, 08:30:02
  • /
  • OTE0001
  • Aussender Logo
  • Grünenthal Group
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Aachen, Germany (OTE) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International....

  • 02.03.2026, 09:55:32
  • /
  • OTE0001
  • Aussender Logo
  • Grünenthal Group
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect

Aachen, Germany & Victoria, Australia (OTE) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique...

  • 24.02.2026, 06:06:03
  • /
  • OTE0001
  • Aussender Logo
  • Grünenthal Group
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development

Aachen, Germany (OTE) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational...

  • 18.02.2026, 10:48:02
  • /
  • OTE0001
  • Aussender Logo
  • Grünenthal Group
Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors

Aachen (OTE) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive...

  • 04.09.2025, 10:03:04
  • /
  • OTE0001
>